Does Rallies show Form 4 insider transactions for AMRX?

Yes. Rallies tracks AMRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is AMRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AMRX. It does not provide personalized investment advice.

AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock) Stock Analysis - Insider Trades

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a publicly traded Healthcare sector company. As of May 21, 2026, AMRX trades at $12.45 with a market cap of $3.80B and a P/E ratio of 31.40. AMRX moved +3.39% today. Year to date, AMRX is -3.78%; over the trailing twelve months it is +64.82%. Its 52-week range spans $6.69 to $15.42. Analyst consensus is strong buy with an average price target of $17.25. Rallies surfaces AMRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading AMRX stock inside the company?

Recent AMRX insider activity includes Autor Deborah M. sold 34.82K, Nark Ted C sold 50.00K, Shah Nikita sold 131.86K, Kiely John sold 32.00K, and Shah Nikita sold 6.34K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

AMRX Key Metrics

Key financial metrics for AMRX
Metric	Value
Price	$12.45
Market Cap	$3.80B
P/E Ratio	31.40
EPS	$0.39
Dividend Yield	0.00%
52-Week High	$15.42
52-Week Low	$6.69
Volume	1.20M
Avg Volume	0
Revenue (TTM)	$3.05B
Net Income	$181.31M
Gross Margin	38.66%

Recent AMRX Insider Trades

Autor Deborah M. sold 34.82K (~$450.56K) on May 11, 2026.
Nark Ted C sold 50.00K (~$586.00K) on Nov 17, 2025.
Shah Nikita sold 131.86K (~$1.57M) on Nov 12, 2025.
Kiely John sold 32.00K (~$295.36K) on Aug 27, 2025.
Shah Nikita sold 6.34K (~$60.23K) on Aug 25, 2025.

Latest AMRX News

Amneal Q1 Revenue $723M Up 4%, Specialty Segment Grows 23% — May 7, 2026
Amneal Launches First U.S. MDIs Targeting $1.5B Albuterol and $321M Beclomethasone Markets — Apr 14, 2026
Amneal Guides 2026 Sales to $3.05–3.10B with Flat Specialty Growth — Apr 11, 2026
Amneal Debuts Bimatoprost 0.01% Generic in Three Sizes with $719M U.S. Sales — Apr 9, 2026
Amneal’s $2 Million Parkinson’s Patient Copay Support Program — Apr 7, 2026

AMRX Analyst Consensus

5 analysts cover AMRX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.25.

Common questions about AMRX

Who is trading AMRX stock inside the company?: Recent AMRX insider activity includes Autor Deborah M. sold 34.82K, Nark Ted C sold 50.00K, Shah Nikita sold 131.86K, Kiely John sold 32.00K, and Shah Nikita sold 6.34K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for AMRX?: Yes. Rallies tracks AMRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is AMRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AMRX. It does not provide personalized investment advice.